The intention of this study was not to develop an alternative to short-lived radiotracers, but to expand the range of available PET tracers if, despite rising prostate-specific antigen (PSA) values, no convincing tumor detection with Ga-68 or F-18 PSMA tracers is possible. The gene discussed is FOLH1; the disease is neoplasm.